JPRN-UMIN000026925已完成未知
Combination therapy of immuno checkpoint inhibitors and radiosensitization treatment for metastatic melanoma - Immuno-radiosensitization treatment for metastatic melanoma
Kochi University, Kochi Medical School0 个研究点目标入组 5 人开始时间: 2017年4月10日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 95years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Unable to secure infusion route of drugs by using ultrasound or CT 2) Determined to have high risk for bleeding by principalinvestigator or sub-investigators 3) Determined to have high risk for infection by principalinvestigator or sub-investigators 4) Determined to be inappropriate for this trial.
研究者
相似试验
尚未招募
不适用
Administration of immune checkpoint inhibitors through an elastomeric pump. A patient preference study and cost analysis.Solid tumors for which nivolumab or pembrolizumab monotherapy has an EMA approved indication. This includes (but is not limited to) melanoma, renal-cell cancer, NSCLC and head and neck cancer.NL-OMON25676Erasmus MC390
进行中（未招募）
1 期
Patient preference for administration of cancer immunotherapy via an elastomeric pump. A patient preference study and an economic analysis.Solid tumors for which nivolumab or pembrolizumab monotherapy is an EMA approved indication. This includes (but is not limited to) melanoma, renal-cell cancer, NSCLC and head and neck cancer.EUCTR2021-000058-24-NLErasmus MC Cancer Institute390
招募中
4 期
Administration of immune checkpoint inhibitors through an elastomeric pump. A patient preference study and cost analysis.NSCLC and head and neck cancerrenal-cell cancerSolid or hematological tumors for which Nivolumab or Pembrolizumab monotherapy have an EMA approved indication. This includes (but is not limited to) melanomaVarious forms of cancer for which Nivolumab or Pembrolizumab monotherapy are prescribed as treatment10027656NL-OMON54425Erasmus MC, Universitair Medisch Centrum Rotterdam390
尚未招募
Unknown
Immune checkpoint inhibitor therapy for advanced, recurrent or metastatic non-small cell lung cancer with low or negative PD-L1 expression.JPRN-UMIN000050723Kobe University200
已完成
不适用
Combined therapy with immune-suppressive drug in children with immunoglobulin resistant Kawasaki diseaseKawasaki diseaseJPRN-UMIN000032096Dokkyo medical university52